Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXUCSN)

Drug Name
NPY5RA-972 Drug Info
Synonyms
NPY 5RA972; 439861-56-0; CHEMBL325226; N-[4-METHYL-9-(1-METHYLETHYL)-9H-CARBAZOL-3-YL]-4-MORPHOLINECARBOXAMIDE; SCHEMBL6826732; CTK8F0016; DTXSID30432395; MolPort-023-276-896; ZINC27101553; BDBM50116592; AKOS024457744; NCGC00370914-01; RT-014756; B7466; N-(4-Methyl-9-isopropyl-9H-carbazole-3-yl)morpholine-4-carboxamide; Morpholine-4-carboxylic acid (9-isopropyl-4-methyl-9H-carbazol-3-yl)-amide
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Preclinical [1]
Cross-matching ID
PubChem CID
9884833
CAS Number
CAS 439861-56-0
TTD Drug ID
DMXUCSN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuropeptide Y receptor type 5 (NPY5R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP71683A DMRYC08 Obesity 5B81 Discontinued in Phase 3 [2]
Velneperit DMROSHN Obesity 5B81 Discontinued in Phase 2 [3]
S-234462 DM80P4U Obesity 5B81 Discontinued in Phase 1 [3]
Axovan-3 DM1JN6A Eating disorder 6B82 Discontinued in Phase 1 [4]
FR-79620 DMXR287 Diabetic complication 5A2Y Preclinical [1]
GW-594884A DMHUD27 Obesity 5B81 Preclinical [1]
RWJ-49815 DMUGZMO Fungal infection 1F29-1F2F Terminated [4]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [5]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH Discovery agent N.A. Investigative [6]
S-25585 DMBUD1M Eating disorder 6B82 Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Antagonist [1]

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
3 Clinical pipeline report, company report or official report of Shionogi (2011).
4 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
5 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
6 Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.